Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_assertion type Assertion NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_head.
- NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_assertion description "[Cutaneous malignant tumors are the most frequent adverse events of BRAF inhibitors; therefore, strict dermatologic surveillance in a referral center aided by digital follow-up is mandatory, especially when multiple nevi are present and these drugs are used in an adjuvant setting.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_provenance.
- NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_assertion evidence source_evidence_literature NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_provenance.
- NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_assertion SIO_000772 25651238 NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_provenance.
- NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_assertion wasDerivedFrom befree-2016 NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_provenance.
- NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_assertion wasGeneratedBy ECO_0000203 NP1260962.RAh-7301jvl6yehKZpLFCzrjy4ZWxPQnbFafNEk9kwWd4130_provenance.